Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

ResMed Revenue Surges 15 Percent in Q3

San Diego-based ResMed reported $591.6 million in third quarter revenue, a 15 percent year-over-year increase.

Outpatient Sites Become A Central Part of Care

HEALTH: Revenue Needs, Market Trends Push Change

San Diego hospitals in the last few years boosted investment in modest freestanding centers for surgery, imaging and other services, vying for patients seeking convenience and lower costs.

Tease photo

Acadia’s Stock Falls on FDA Reexamination

The U.S. Food and Drug Administration said it was reexamining San Diego-based Acadia Pharmaceuticals’ drug to treat hallucinations and delusions caused by Parkinson’s disease. The news was first reported by CNN on April 25.

Illumina’s Revenue Increase Tops Analysts’ Expectations

Illumina reported $782 million in first quarter revenue, a 31 percent year-over-year increase, the company announced April 24.

Dthera Sciences Appoints Steve Martin to Board

Steve Martin, a seasoned CFO, has joined Dthera Sciences’ board.

Skaggs School Launches Masters Degree for Drug Development, Management

UC San Diego’s Skaggs School of Pharmacy and Pharmaceutical Sciences has launched a master of science in drug development and product management, a first-of-its-kind offering.

Organovo’s Money Is on Measured Advances

BIotECH: Model for NASH Drug Testing,Tissue for Bridge Solutions Are Goals

Organovo’s technology sounds straight out of science fiction movies: 3-D printed tissues that emulate human organs. But, this story is shifting.

Tease photo

Orexigen Agrees to Sell Its Assets to Nalpropion for $75M

Orexigen agrees to sell its assets.

Ionis Inks $1 Billion Deal with Biogen

Biogen will pay Carlsbad’s Ionis Pharmaceuticals $1 billion in cash as part of a 10-year collaboration around neurological drug development.

ResMed’s CEO Eyes Greater Market Share

BIOTECH: Software Success To Move On to Analytics, AI

Five years ago, Michael “Mick” Farrell listened to an analyst forecast ResMed’s demise.

Tease photo

Tocagen Licenses Its Immunotherapy in China

Citing regulatory changes, San Diego’s Tocagen licensed its immunotherapy for commercialization in China, earning the company $16 million upfront and potentially much more.

French Company Acquires Astute Medical for $90 Million

French diagnostics giant bioMérieux acquired San Diego-based Astute Medical in a $90 million cash deal announced earlier this month.

Grossmont Clinic for Non-Emergency Conditions Opens

Sharp Grossmont Hospital has opened a new clinic, which looks to reduce patient volumes in the hospital’s emergency room, one of the busiest in San Diego County.

Irwin Jacobs, Martin Wygod Join Biological Dynamics Board

Biological Dynamics, a San Diego cancer diagnostics company, named Irwin Jacobs and Martin Wygod to its board, it was announced April 13.

Tandem Diabetes Care Continues Momentum in Preliminary Q1 Results

Tandem Diabetes Care reported a 42 percent year-over-year increase in preliminary quarter one sales, increasing the company’s stock.

Tandem Turnaround Focuses on Execution

BIOTECH: Partnership, Sales Boost Are Part of Positives

Tandem Diabetes Care believes the storm has passed.

Tease photo

Turbocharging Electronic Health Records With AI

BIOTECH: Optum360’s System Covers All the Bases for Variety of Users

A San Diego offshoot is deploying artificial intelligence against a crushing administrative burden: electronic health records.

Tease photo

ResMed Hires CTO

San Diego-based ResMed has hired Bobby Ghoshal as the company’s first chief technology officer.

Tease photo

Sharp HealthCare’s CEO to Retire

After 22 years as Sharp Healthcare’s CEO, Michael Murphy plans to retire February 2019.

Conflict of Interest At Center of Lawsuit

LEGAL: Avoiding It Can Be Tricky for Law Firms

A Carlsbad spine surgery company recently sued a law firm, highlighting a thicket of conflict-of-interest issues lawyers wade through in choosing clients.

Arcturus Therapeutics Sues Former CEO

Arcturus Therapeutics is suing its former CEO, nearly two months after he challenged the legality of the company terminating him.

Singlera Genomics Raises $60 Million in Series A+ Round

La Jolla-based Singlera Genomics has raised $60 million in a Series A+ round, which will go toward development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies.

FDA Approves Dexcom’s G6 Glucose Monitoring

The U.S. Food and Drug Administration signed off on San Diego-based Dexcom’s G6 diabetes monitoring system, which doesn’t require finger prick blood draws for calibration, it was announced March 27.

Luna DNA Adds to Leadership Team, Sets Up in Solana Beach

Luna DNA, a startup led by former Illumina executives, has filled out its leadership roster.

Toft Group Hires COO

Ronald Giannotti has been appointed as COO of Toft Group Executive Search, a San Diego-based firm centered on executive searches in life sciences and health care.

Tease photo

Center for Medical Device Manufacturing Opens in Carlsbad

A biomedical incubator has opened facilities for additive manufacturing and R&D in Carlsbad to aid medical device product development.

Deal Gives Vividion Small Molecule War Chest

BIOTECH: Co. to Take on Previously ‘Undruggable’ Proteins

Even by startup standards, Vividion Therapeutics CEO Diego Miralles makes bold claims. He said the venture marks a “once-in-a-generation opportunity” to build a transformative company in San Diego.

Tease photo

Human Longevity Taps Scott Sorensen as CTO

San Diego’s Human Longevity, Inc. has named Scott Sorensen chief technology officer as the company brings its genomics and health program to more locations globally.

Heron Therapeutics’ Stock Rises on Data for Opioid Alternative Anesthetic

A Heron Therapeutics postoperative pain anesthetic billed as an alternative to opioids achieved positive late-stage trial results, boosting the San Diego company’s stock.

Twist Bioscience Opens Carlsbad Office

San Francisco-based Twist Bioscience Corporation has opened a 2,500-square-foot office in Carlsbad.

Daré Bioscience Enters into Development Agreement

Daré Bioscience, a San Diego biopharmaceutical focused on women’s reproductive health, has partnered with Orbis Biosciences to develop long-lasting injectable contraceptives.

Making Machines Work for Co., Clinic

BIOTECH: Illumina SVP Tackles Challenges

Susan Tousi doesn’t practice medicine, unlike many in her family tree. But Illumina’s senior vice president of product development is making her mark on health.

Tease photo

Alphatec Raises $50 Million, Acquires SafeOp

In a flurry of moves announced March 8, Alphatec acquired SafeOp Surgical, raised $50 million and installed Patrick Miles as CEO.

Crinetics Pharmaceuticals Raises $63.5M

San Diego biotech Crinetics Pharmaceuticals, taking aim at endocrine-related cancers and endocrine disorders, raised $63.5 million through a Series B financing round.

Ionis Spinout to Commercialize Inotersen

Carlsbad’s Ionis Pharmaceuticals is entrusting Akcea Therapeutics, a spinout of Ionis, to commercialize the drug inotersen ahead of a showdown.

Drug Salvage Operation May Be Salvation for Cancer Victims

John Hood turned a cast-off drug into a multibillion deal.

Tease photo

Edico Takes Big Step Into Medical Records

BIOTECH: Partnership to Put Genomics Data in Files

San Diego’s Edico Genome recently inked a deal to incorporate genomics data into electronic medical records, a cutting-edge space for which the company appears to be well positioned.

Tease photo

Crinetics Pharmaceuticals Raises $63.5 Million in Series B Round

San Diego biotech Crinetics Pharmaceuticals, taking aim at endocrine-related cancers and endocrine disorders, raised $63.5 million through a Series B financing round.

Bankruptcy Sale on Tap for Orexigen Therapeutics

Orexigen’s weight-loss prescription drug, Contrave, didn’t meet sales expectations, running afoul of an agreement with creditors, according to court documents.

Reed to Retire as Sempra CEO

Sempra Energy CEO and president Debra Reed plans to retire in May, ending a 40-year career with Sempra companies, and on the heels of a multi-billion deal.

Alphatec Raises $50 Million, Acquires SafeOp

In a flurry of moves announced this week, Alphatec acquired SafeOp Surgical, raised $50 million and installed Patrick Miles as CEO.

Forge Therapeutics Expands to New Office

San Diego biotech Forge Therapeutics, dedicated to fighting superbugs, is expanding to a 7,000-square-foot space in Torrey Mesa.

Platform Delivers For Halozyme

BIOTECH: Co. Finds Right Balance for Work On Drug, Delivery System

Halozyme Therapeutics seeks big returns on two fronts. Royalties in one could hit nearly $1 billion by 2027. The other holds even bigger potential.

Tease photo

Texas Regulators Approve Sempra Buying Oncor for $9.45B

The Public Utility Commission of Texas on March 8 approved Sempra Energy buying Oncor Electric Delivery, the last remaining regulatory obstacle in a $9.45 billion deal expected to close shortly.

$140M UC San Diego Health Outpatient Pavilion to Debut

On March 12, UC San Diego Health will open the Koman Family Outpatient Pavilion, sporting specialty services for breast, urology, sports medicine and spine care.

Tease photo

Vividion Locks Down $101M Upfront in Celgene Collaboration

The San Diego biotech will receive the payment as part of a four-year collaboration with Celgene.

Poseida Therapeutics Names Mark Gergen as CBO, CFO

Mark J. Gergen has joined San Diego-based Poseida Therapeutics as chief business officer and chief financial officer, bringing 25 years of life sciences experience.

Co.’s Rodent Testing Niche Aims for NASH Treatment

Clients of Carlsbad’s Triangulum Biopharma include the likes of NASA, or National Aeronautics and Space Administration. Yet Triangulum won’t comment on the specific nature of the contract.

Tease photo

Ionis Reports Promising Huntington’s Disease Drug Trial

The Carlsbad drugmaker reported positive early stage data on a potentially groundbreaking drug to reduce the underlying cause of Huntington’s Disease.

Beacon Discovery, Takeda Ink Deal

San Diego’s Beacon Discovery formed a multi-year drug discovery collaboration with Takeda Pharmaceutical Company centered on gastrointestinal disorders.

Prev